Expert Interview
A Second Look: Discussing the standard of care and the potential of NAYZILAM (midazolam), a nasal spray able to return patients experiencing seizure clusters back to baseline function within 90 minutes
Ticker(s): UCBInstitution: University Hospitals
- Neurologist and epilepsy specialist at University Hospitals and professor of pediatrics and neurology at Case Western Reserve University School of Medicine.
- Currently manages >25 patients with seizure clusters
- Familiar with the results from the Phase 3 open-label extension study which evaluated the safety of repeated, intermittent use of NAYZILAM in patients that experience seizure clusters
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
